105 related articles for article (PubMed ID: 22324951)
1. Low C3 levels is associated with neutropenia in a proportion of patients with myelodysplastic syndrome: retrospective analysis.
Kim KJ; Kwok SK; Park YJ; Kim WU; Cho CS
Int J Rheum Dis; 2012 Feb; 15(1):86-94. PubMed ID: 22324951
[TBL] [Abstract][Full Text] [Related]
2. The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome.
Cordoba I; Gonzalez-Porras JR; Such E; Nomdedeu B; Luño E; de Paz R; Carbonell F; Vallespi T; Ardanaz M; Ramos F; Marco V; Bonanad S; Sanchez-Barba M; Costa D; Bernal T; Sanz GF; Cañizo MC
Leuk Res; 2012 Mar; 36(3):287-92. PubMed ID: 22133642
[TBL] [Abstract][Full Text] [Related]
3. [Clinical features and survival analysis in primary myelodysplastic syndromes patients with immunological abnormalities].
Li B; Xu ZF; Cui R; Chen YD; Su T; Zhang TJ; Fang LW; Zhang HL; Qin TJ; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2012 Jul; 33(7):527-31. PubMed ID: 22967411
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous manifestations in relation to immunologic parameters in a cohort of primary myelodysplastic syndrome patients.
Dalamaga M; Karmaniolas K; Matekovits A; Migdalis I; Papadavid E
J Eur Acad Dermatol Venereol; 2008 May; 22(5):543-8. PubMed ID: 18070024
[TBL] [Abstract][Full Text] [Related]
5. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
Kao JM; McMillan A; Greenberg PL
Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
[TBL] [Abstract][Full Text] [Related]
6. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.
Raptis A; Duh MS; Wang ST; Dial E; Fanourgiakis I; Fortner B; Paley C; Mody-Patel N; Corral M; Scott J
Transfusion; 2010 Jan; 50(1):190-9. PubMed ID: 19719471
[TBL] [Abstract][Full Text] [Related]
7. Myelodysplasia and autoimmunity.
Giannouli S; Kanellopoulou T; Voulgarelis M
Curr Opin Rheumatol; 2012 Jan; 24(1):97-102. PubMed ID: 22157417
[TBL] [Abstract][Full Text] [Related]
8. Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count.
Jacobs NL; Holtan SG; Porrata LF; Markovic SN; Tefferi A; Steensma DP
Am J Hematol; 2010 Mar; 85(3):160-3. PubMed ID: 20131304
[TBL] [Abstract][Full Text] [Related]
9. [The myelodysplastic syndrome and autoimmunity].
Laursen SB; Nielsen MØ; Hasselbalch HC
Ugeskr Laeger; 2009 Sep; 171(37):2639-42. PubMed ID: 19758507
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome.
Gonzalez-Porras JR; Cordoba I; Such E; Nomdedeu B; Vallespi T; Carbonell F; Luño E; Ardanaz M; Ramos F; Pedro C; Gomez V; de Paz R; Sanchez-Barba M; Sanz GF; Del Cañizo AC;
Cancer; 2011 Dec; 117(24):5529-37. PubMed ID: 21638279
[TBL] [Abstract][Full Text] [Related]
11. [Changes of the complement system in myelodysplastic syndromes].
Villaescusa Blanco R; Arce AA; Santos RM; Fernández N
Sangre (Barc); 1998 Jun; 43(3):210-2. PubMed ID: 9741227
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the prognostic significance of eosinophilia and basophilia in a larger cohort of patients with myelodysplastic syndromes.
Wimazal F; Germing U; Kundi M; Noesslinger T; Blum S; Geissler P; Baumgartner C; Pfeilstoecker M; Valent P; Sperr WR
Cancer; 2010 May; 116(10):2372-81. PubMed ID: 20209617
[TBL] [Abstract][Full Text] [Related]
13. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
14. Clinical course of patients with aplastic anemia or myelodysplastic syndrome associated with persistent neutropenia.
Kako S; Nakasone H; Endo H; Sakamoto K; Ashizawa M; Sato M; Terasako K; Kikuchi M; Kimura S; Okuda S; Yamazaki R; Oshima K; Tanihara A; Nishida J; Usuki K; Kanda Y
Hematol Oncol; 2012 Jun; 30(2):82-8. PubMed ID: 21692099
[TBL] [Abstract][Full Text] [Related]
15. Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes.
Loeffler-Ragg J; Germing U; Sperr WR; Herrmann H; Zwierzina H; Valent P; Ulmer H; Stauder R
Crit Rev Oncol Hematol; 2011 May; 78(2):150-61. PubMed ID: 20580567
[TBL] [Abstract][Full Text] [Related]
16. [An analysis of prognostic factors in 80 myelodysplastic syndrome].
Xu XQ; Wang JM; Lu SQ; Chen L; Yang JM; Zhang WP; Song XM; Xu YQ; Gong SL; Hou J; Ni X
Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):723-7. PubMed ID: 19176004
[TBL] [Abstract][Full Text] [Related]
17. Outcome of patients with myelodysplastic syndromes: experience from a single institution in South Australia.
Hui CH; Horvath N; Lewis I; To LB; Szabo F
Intern Med J; 2008 Nov; 38(11):824-8. PubMed ID: 18284457
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and prognostic value of cutaneous manifestations in patients with myelodysplastic syndrome.
Farah C; Bulai Livideanu C; Jegu J; Paul C; Viraben R; Lamant L; Delavigne K; Adoue D; Laurent G; Beyne Rauzy O
J Eur Acad Dermatol Venereol; 2010 Oct; 24(10):1171-5. PubMed ID: 20202054
[TBL] [Abstract][Full Text] [Related]
19. Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study.
Giannouli S; Voulgarelis M; Zintzaras E; Tzioufas AG; Moutsopoulos HM
Rheumatology (Oxford); 2004 May; 43(5):626-32. PubMed ID: 14983106
[TBL] [Abstract][Full Text] [Related]
20. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
